>>> Anadarko Petroleum misses by $0.40, beats on revs, cuts CapEx by $300 mln, m

Anadarko Petroleum misses by $0.40, beats on revs, cuts CapEx by $300 mln, maintains expected oil production exit rates
  • Reports Q2 (Jun) loss of $0.75 per share, excluding non-recurring items, $0.40 worse than the Capital IQ Consensus of ($0.35); revenues rose 41.8% year/year to $2.72 bln vs the $2.5 bln Capital IQ Consensus
  • Achieved a 12% increase in total oil sales volume over the second quarter of 2016
  • Increased overall sales-volume product mix to 67% liquids compared to 54% liquids in the second quarter of 2016
  • Anadarko's second-quarter 2017 sales volume of oil, natural gas and natural gas liquids (NGLs) totaled 57 million barrels of oil equivalent (BOE), or an average of 631,000 BOE per day. During the second quarter, Anadarko achieved record oil sales volume in the Delaware Basin of West Texas averaging ~33,000 barrels of oil per day, a 52% increase over the second quarter of 2016
  • Importantly, Anadarko is in the final stages of securing operatorship for ~70% of the acreage position, which was previously part of the joint-venture agreement that recently concluded with Shell
  • Also, the co said, "Our portfolio delivered good operating results and cash flow during the second quarter with significantly improved cash margins and increased oil volumes year-over-year, even with the temporary production impacts associated with our response efforts in Colorado. Our successful divestitures further strengthened the company's cash position, while providing flexibility for the second half of the year and beyond. The current market conditions require lower capital intensity given the volatility of margins realized in this operating environment. As such, we are reducing our level of investments by $300 million for the full year, and adjusting full-year sales-volume guidance to reflect recent divestitures and the deferred production associated with the Colorado response. We feel this is a prudent move, while still expecting to average ~130,000 barrels of oil per day in the deepwater Gulf of Mexico and exit the year at around 150,000 barrels of oil per day from the Delaware and DJ basins combined."

>>> Alphabet beats by $0.58, beats on revs --> GOOG -3.16%

Alphabet beats by $0.58, beats on revs
  • Reports Q2 (Jun) earnings of $5.01 per share, $0.58 better than the Capital IQ Consensus of $4.43; revenues rose 21.0% year/year to $26.01 bln vs the $25.61 bln Capital IQ Consensus.
    • Operating Margin 16% compared to 28% in prior year; Recall this year includes the $2.7 bln fee paid to the EU.
    • Google Properties revenue $18.42 bln, +19.6% y/y.
    • Google Network Members properties revenue $4.24 bln, +13% y/y
    • Other Bets Revenue- $248 mln, +34% y/y; Other Bets operating loss was ($772 mln), compared to street expectations of ($970 mln)
    • Total TAC as a percentage of revenue was 22% compared to 21% in prior year period.
  • Aggregate Clicks Paid: 52%; Q1 +44%; Q4 +36%, Q3 +33%; Q2 +29%.
      • Paid Click on Google Properties +61%
      • Paid Clicks on Google Network Member +9%
  • Aggregate cost per click: -23%; Q1 -19%; Q4 -15%, Q3 -11%; Q2 -7%,
    • CPC on Google Properties -26%
    • CPC on Google Network Members properties -11%
  • On June 27, 2017, the EC announced its decision that certain actions taken by Google regarding its display and ranking of shopping search results and ads infringed European competition law. The EC decision imposes a €2.42 billion (approximately $2.74 billion) fine, which we accrued in the second quarter of 2017. The fine is included in "accrued expense and other current liabilities" on our Consolidated Balance Sheet.

>>> Lyxor: Hedge Fund Index Flat For 2017 As Event-Driven, Equity Strategies Shi

J
Hedge funds were flat again last week as gains in event-driven, L/S Equity and CTA funds were offset by a decline in Global Macro strategies, according to Lxyor Asset Management’s latest research.
The company’s Lyxor Hedge Fund Index returned exactly 0.0% for the week through July 18, Lyxor said in its most recent Weekly Brief. In what is very likely to be a very uncommon occurrence this late in an annual cycle, the index’s month-to-date and year-to-date returns are also 0.0%.
CTAs edged higher last week, gaining 0.5% as gains in equities and fixed income were in line with their positioning. The strategy remains short USD, in particular against EM currencies as well as EUR, and remains down -3.9% YTD. Event-Driven strategies also extended their winning streak last week on the back of positions in the technology, consumer non cyclical and communications sectors, gaining 0.7% to push YTD gains to 6.3%. Global Macro, conversely, lost 0.5% due to headwinds related to the rise of the EUR versus the dollar and the underperformance of European stocks. Global Macro is now down -3.6% for the year so far.
A rising tide lifts all boats, Lyxor noted in the research note, observing how the sharp outperformance of technology stocks lifted the S&P 500 to new records last week, which in turn drove the MSCI World index to new records. The market developments have had significant implications for hedge fund performance, Lyxor said, as Event-Driven and L/S Equity exposure to technology stocks helps explain why both strategies outperformed last week.
“Going forward, we maintain an overweight stance on Event-Driven and Fixed Income Arbitrage,” added Lyxor senior strategist Philippe Ferreira in the note. “We also reiterate the overweight stance on EM focused macro managers. In parallel, we advise an underweight stance on CTAs and L/S Equity market neutral strategies and have L/S Equity and L/S Credit at neutral.”
Lyxor’s Weekly Brief aims to identify trends in hedge fund investing while leveraging the proprietary information accessible through the company’s managed account platform.
Lyxor’s Hedge Fund indices are based on the universe of funds available on the platform determined on a monthly basis to be eligible for inclusion. Participating funds represent $12 billion of assets under management and replicating $220 billion in AUM as of June 30, 2017.

WSJ : Board Practices Hurt Banco Popular, Experts Say

Board Practices Hurt Banco Popular, Experts Say
The problems at the Spanish lender went beyond the bank run that forced a European Central Bank rescue

When Europe’s central bank orchestrated an overnight rescue of Banco Popular Español SA in June, the immediate spark was a bank run that left the Spanish lender close to collapse.

But Banco Popular’s problems ran deeper, touching an area that has been devilishly difficult for European regulators to address: poor governance.

The bank’s problems, governance experts say, included board members who weren’t independent enough from management and deals with companies that had ties to the board.

Corporate governance shortcomings are more common in European banks compared with the U.S., experts say. Some attribute the difference to a fragmented continent where countries’ capital markets are in varied stages of development and have different rules and regulations.

“In Europe, you have 28 different banking systems, which were created nationally under different mandates,” said Tom Kirchmaier, deputy director of corporate governance at the London School of Economics.

Since the European Central Bank assumed supervision of major eurozone banks in November 2014, it has stepped up the focus on corporate governance, pressing lenders, for instance, to ensure boards include a sufficient number of independent directors. Since then, the ECB conducted 94 on-site visits to examine governance issues, the second-highest number of inspections after loan risk.

When the ECB began to regulate Banco Popular, Spain’s No. 6 lender by assets, it inherited a bank that analysts say was riddled with governance problems.

In its 2016 annual report, the bank said seven of 15 board members were independent. However, four had longstanding links to Banco Popular, ties that governance experts say undermined their ability to challenge executives’ decisions.

One had served as finance director and chief executive at the bank immediately before becoming a board member. Governance experts say there should be at least a few-years’ “cooling off” period for a director in that situation to be considered independent.

Another member sat on the board for nearly 10 years, a duration governance experts consider too long to be deemed independent.

A third filled in for her father when he stepped down from the board after serving for more than two decades.

A fourth previously had been a nonindependent director representing an investor who remained a significant shareholder.

A Banco Popular spokeswoman said Spain’s securities regulator reviewed and had no objection to the bank’s designation of the board members as independent. A board member can be considered independent for up to 12 years under Spanish law, she noted.

Analysts say that coziness between the board and management contributed to the board’s slowness to remove Ángel Ron as executive chairman, despite investor concern the bank wasn’t doing enough to shed roughly €37 billion in sour loans. Mr. Ron was replaced in December after 12 years at the helm and more than a 90% drop in the bank’s share price.

The bank spokeswoman declined to comment on Mr. Ron’s departure.

Mr. Ron has said the liquidity problems that ultimately triggered Banco Popular’s takeover began after he stepped down, according to people familiar with his reasoning.

“Truly independent board members are key to avoid conflicts of interest that end up impacting stakeholders,” said Carlos García, an analyst with financial services firm Kepler Cheuvreux SA. ”Popular is an example of why governance matters.”

Another issue for Banco Popular was its relationships with firms that had representation on its board.

For example, on June 2 French lender Banque Fédérative du Crédit Mutuel SA, which had one seat on the board, nearly doubled to 100% its stake in a retail bank it managed with Banco Popular. The same day, the French lender’s representative stepped down from the board of the bank. Five days later, Banco Popular was rescued and sold to Spain’s Banco Santander SA for a token €1.

Mr. Kirchmaier said unless the purchase of the stake was ordered by regulators amid the resolution process—which remains unclear—the move raises questions about whether Crédit Mutuel used information garnered in its board capacity to do the deal.

Representatives for Crédit Mutuel declined to comment.

A spokesman for Spain’s market regulator said the ties between Crédit Mutuel and Banco Popular were disclosed and detailed to investors in the bank’s annual reports.

A Banco Popular spokeswoman declined to comment on corporate governance issues. The ECB declined to comment on specific cases.

Banco Popular’s board members also approved deals that made it appear the bank was on sounder financial footing than it was, according to analysts.

In mid-2014, as Banco Popular was struggling to recover from Spain’s financial crisis, the bank sold the rights to the future profits generated by some of its insurance and pension products. The buyer was a newly created firm managed by a sole administrator who was also an employee of Banco Popular, according to the bank’s 2014 and 2015 annual reports.

Banco Popular booked a €97 million profit from the sale.

The bank had also financed 48% of the deal, according to its annual reports. That means Banco Popular was financing its own profits.

That approach can mask the true value of a transaction and is often done when a company is in financial trouble, said James Shein, a professor and corporate governance expert at Northwestern University’s Kellogg School of Management.

“Almost 100% of time there are bank failures, first there was a governance problem,” Mr. Shein said.

Banco Popular said in its annual reports that the deal was done at arm’s length and evaluated by an independent expert.

The bank’s spokeswoman declined to comment.

>>> Oncor to swap assets with Sharyland Utilities in USD 400m deal

Oncor to swap assets with Sharyland Utilities in USD 400m deal
24 JUL 2017
Oncor Electric Delivery Company LLC, a Dallas, Texas-based electricity distributor and transmission provider, will swap distribution assets and customer accounts with Sharyland Utilities, L.P., an Amarillo, Texas-based public utility, in a USD 400m transaction.
In the transaction, SDTS will receive 258 miles of 345 kV transmission lines from Oncor, and Oncor will receive Sharyland's distribution network and retail delivery customers.
This transaction allows Oncor to acquire new customers and continue to expand its service territory.
Oncor Electric Delivery operates the largest distribution and transmission system in Texas, delivering power to more than 3.4 million homes and businesses and operating more than 122,000 miles of transmission and distribution lines in Texas.

FT : Mitsubishi Tanabe to pay $1.1bn for Israeli drugmaker

Mitsubishi Tanabe to pay $1.1bn for Israeli drugmaker
Nasdaq-listed Neuroderm is testing a treatment for Parkinsons

Mitsubishi Tanabe Pharma became the latest Japanese company to target the US’s $450bn drug market by agreeing a $1.1bn takeover of a US-listed Israeli group that is testing a treatment for Parkinson’s disease.

The Japanese company announced it would pay $39 in cash per share to acquire NeuroDerm. The transaction has an enterprise value of a little over $1bn after accounting for NeuroDerm’s excess cash position, or $1.1bn including advisory costs.

Mitsubishi Tanabe, which hopes to establish a franchise around neurological and autoimmune diseases, will separately make its first foray into the US next month with the launch of a treatment for motor neurone disease.

Globally, Japan’s drug market is second only to the US, but the deal is one of an increasing number by Japanese companies trying to diversify away from the domestic market where the government’s sweeping review to make drug prices more affordable to the country’s ageing population threatens earnings. It also represents part of the broader demand for overseas growth that drove foreign acquisitions by Japanese buyers to a record ¥10.9tn ($97.9bn) in the fiscal year ended March 31.

If completed, the NeuroDerm deal would be the third-biggest outbound Japanese drug acquisition this year behind Takeda Pharmaceuticals’ $5.2bn purchase in January of Boston-based cancer drugmaker Ariad, and Sawai Pharmaceuticals buying generics maker Upsher-Smith Laboratories for $1.05bn.

The offer from Mitsubishi Tanabe, which has a market capitalisation of ¥1.49tn, represents a 17.5 per cent premium to NeuroDerm’s closing price on July 21, but a 79 per cent premium to its close on June 9 before media reports that the Tel Aviv-based company was considering a sale.

“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients that urgently need new therapies,” said Oded Lieberman, NeuroDerm’s chief executive.

The Japanese drugmaker generated ‎¥‎22.7bn, or a little more than 5 per cent of total revenue, from overseas sales in the fiscal year ended March 31 and hopes the NeuroDerm deal will “enable” it to achieve its US sales target of ‎¥‎80bn by the end of its 2020 fiscal year.

“The model used by pharmaceutical manufacturers has been to cover their fixed costs in the Japanese domestic market and to earn profits in overseas markets, with the US as the main target. We expect the shift in focus to overseas markets to gather momentum,” noted Fumiyoshi Sakai, an analyst at Credit Suisse.

NeuroDerm, which had 77 employees as of March, will become the sole entity within Mitsubishi Tanabe’s Israel-established subsidiary, which would make it a wholly-owned subsidiary of the Japanese company in a so-called reverse triangular merger.

Mitsubishi Tanabe said it had secured the support of three of NeuroDerm’s directors who collectively own 33.7 per cent of the company’s stock.

The deal, which is subject to shareholder approval, would be one of the biggest in Israeli corporate history. Earlier this year tech giant Intel bought Mobileye, a developer of self-driving car technologies, for $15.3bn, the largest takeover in Israeli history.

Shares in Mitsubishi Tanabe Pharma closed 1.2 per cent lower in Tokyo on Monday, a little more than double the decline for the broader Japanese stock market. Shares in Neuroderm shot up 15 per cent in premarket New York trading to just below $39.